Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of 1H-Benzotriazole-1-methanamine, N,N-bis(2-ethylhexyl)-6-methyl- and 2H-Benzotriazole-2-methanamine, N,N-bis(2-ethylhexyl)-5-methyl- and N,N-bis(2-ethylhexyl)-4-methyl-1H-benzotriazole-1-methylamine and 2H-Benzotriazole-2-methanamine, N,N-bis(2-ethylhexyl)-4-methyl- and N,N-bis(2-ethylhexyl)-5-methyl-1H-benzotriazole-1-methylamine
EC number: 939-700-4 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Systemic availability is likely for one or several of the constituents or their metabolites. There are no experimental data to prove a bioaccumulating potential.
Key value for chemical safety assessment
Additional information
The substance is a multi-constituent product with a low water solubility (< 0.02 mg/L at 23 °C) and a log Pow of 7.6 -8.2 (calculated). The vapor presser of the substance is <0.000001 hPa at 25°C, thus inhalation of vapors is unlikely.
The test item hydrolyses directly and quantitatively when it is solved in the buffer solutions. Thus the test item is not considered to be hydrolytically stable at pH 4, 7 and 9. The determination of the hydrolysis rate is not possible because of the very fast hydrolysis.
The following transformation products was detected: Tolyltriazole (CAS No. 29385-43-1). Formaldehyde (CAS No. 50-00-0), Bis(2-ethylhexyl)amine (CAS No. 106-20-7) were proposed as further degradation products.
Simulation of microbial metabolism suggests tolylbenzotriazole (TTZ) as the predominant metabolite (OECD Toolbox, version 2.0). Therefore it can be expected that cleavage of the bulky molecules already takes place in the gastro-intestinal tract to some extent presenting TTZ and alkylamines for an enhanced uptake and distribution. Systemic exposure could not be proven since compound-related findings were not evident other than stress-related effects seen in thymus and spleen. Clinical findings including mortality were observed suggesting uptake to some extent.
Metabolic behaviour is supposed to be similar for a structural analogue (see chapter 7.6.1 for details on molecule). It is postulated that this substance yields to the main metabolite methylbenzotriazole after gastro-intestinal and/or liver cleavage.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
